These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 3361379)

  • 1. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.
    Claesson BA; Trollfors B; Lagergard T; Taranger J; Bryla D; Otterman G; Cramton T; Yang Y; Reimer CB; Robbins JB
    J Pediatr; 1988 May; 112(5):695-702. PubMed ID: 3361379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age.
    Claesson BA; Schneerson R; Lagergård T; Trollfors B; Taranger J; Johansson J; Bryla D; Robbins JB
    Pediatr Infect Dis J; 1991 Aug; 10(8):560-4. PubMed ID: 1891286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.
    Schneerson R; Robbins JB; Parke JC; Bell C; Schlesselman JJ; Sutton A; Wang Z; Schiffman G; Karpas A; Shiloach J
    Infect Immun; 1986 May; 52(2):519-28. PubMed ID: 3516876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children.
    Siber GR; Santosham M; Reid GR; Thompson C; Almeido-Hill J; Morell A; deLange G; Ketcham JK; Callahan EH
    N Engl J Med; 1990 Nov; 323(20):1387-92. PubMed ID: 2233905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates.
    Schneerson R; Robbins JB; Chu C; Sutton A; Vann W; Vickers JC; London WT; Curfman B; Hardegree MC; Shiloach J
    Infect Immun; 1984 Sep; 45(3):582-91. PubMed ID: 6332076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month-old children.
    Claesson BA; Schneerson R; Trollfors B; Lagergård T; Taranger J; Robbins JB
    J Pediatr; 1990 Jun; 116(6):929-31. PubMed ID: 2348298
    [No Abstract]   [Full Text] [Related]  

  • 7. The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK.
    Hazlewood M; Nusrat R; Kumararatne DS; Goodall M; Raykundalia C; Wang DG; Joyce HJ; Milford-Ward A; Forte M; Pahor A
    Clin Exp Immunol; 1993 Aug; 93(2):157-64. PubMed ID: 8348740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.
    Chu C; Schneerson R; Robbins JB; Rastogi SC
    Infect Immun; 1983 Apr; 40(1):245-56. PubMed ID: 6601061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia.
    Sarnaik S; Kaplan J; Schiffman G; Bryla D; Robbins JB; Schneerson R
    Pediatr Infect Dis J; 1990 Mar; 9(3):181-6. PubMed ID: 2336298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients.
    Barra A; Cordonnier C; Preziosi MP; Intrator L; Hessel L; Fritzell B; Preud'homme JL
    J Infect Dis; 1992 Nov; 166(5):1021-8. PubMed ID: 1402013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age.
    Parke JC; Schneerson R; Reimer C; Black C; Welfare S; Bryla D; Levi L; Pavliakova D; Cramton T; Schulz D
    J Pediatr; 1991 Feb; 118(2):184-90. PubMed ID: 1993943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative and quantitative analyses of the antibody response elicited by Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in adults with IgG subclass deficiencies and frequent infections.
    Avanzini MA; Björkander J; Söderström R; Söderström T; Schneerson R; Robbins JB; Hanson LA
    Clin Exp Immunol; 1994 Apr; 96(1):54-8. PubMed ID: 8149666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid.
    Bernstein HH; Seyferth ER
    Vaccine; 2017 Dec; 35(48 Pt B):6707-6711. PubMed ID: 29054729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
    Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine.
    Claesson BA; Trollfors B; Lagergård T; Knutsson N; Schneerson R; Robbins JB
    Pediatr Infect Dis J; 2005 May; 24(5):463-4. PubMed ID: 15876951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
    J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.
    Marshall GS; Blatter M; Marchant C; Aris E; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2013 Jun; 32(6):662-8. PubMed ID: 23340564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.